Biotechnology Assets S.A. (BST) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biotechnology Assets S.A. (BST) has a cash flow conversion efficiency ratio of 0.102x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€658.13K ≈ $769.43K USD) by net assets (€6.45 Million ≈ $7.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Biotechnology Assets S.A. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Biotechnology Assets S.A. - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Biotechnology Assets S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biotechnology Assets S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biotechnology Assets S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CAM Resources Bhd
KLSE:7128
|
0.214x |
|
COCRYSTAL PHARMA NEW O.N.
F:8CC
|
-0.274x |
|
Asia Seed Co.Ltd
KQ:154030
|
-0.017x |
|
Opthea Ltd
AU:OPT
|
0.460x |
|
Prochem S.A.
WAR:PRM
|
0.020x |
|
Schroder Asia Pacific Fund
LSE:SDP
|
0.001x |
|
Accent Resources NL
AU:ACS
|
-0.036x |
|
Volt Carbon Technologies Inc
V:VCT
|
-0.075x |
Annual Cash Flow Conversion Efficiency for Biotechnology Assets S.A. (2014–2024)
The table below shows the annual cash flow conversion efficiency of Biotechnology Assets S.A. from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Biotechnology Assets S.A..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €6.61 Million ≈ $7.73 Million |
€-73.85K ≈ $-86.34K |
-0.011x | -252.87% |
| 2023-12-31 | €6.53 Million ≈ $7.64 Million |
€47.74K ≈ $55.81K |
0.007x | +101.63% |
| 2022-12-31 | €3.87 Million ≈ $4.53 Million |
€-1.73 Million ≈ $-2.03 Million |
-0.447x | -29.25% |
| 2021-12-31 | €4.34 Million ≈ $5.07 Million |
€-1.50 Million ≈ $-1.76 Million |
-0.346x | -115.13% |
| 2020-12-31 | €3.84 Million ≈ $4.49 Million |
€8.79 Million ≈ $10.28 Million |
2.288x | +214.10% |
| 2019-12-31 | €7.56 Million ≈ $8.84 Million |
€-15.16 Million ≈ $-17.72 Million |
-2.005x | -226.35% |
| 2018-12-31 | €21.19 Million ≈ $24.78 Million |
€-13.02 Million ≈ $-15.23 Million |
-0.614x | -2410.54% |
| 2017-12-31 | €8.03 Million ≈ $9.38 Million |
€213.49K ≈ $249.59K |
0.027x | -92.21% |
| 2016-12-31 | €7.96 Million ≈ $9.30 Million |
€2.71 Million ≈ $3.17 Million |
0.341x | +1533.30% |
| 2015-12-31 | €7.57 Million ≈ $8.85 Million |
€158.16K ≈ $184.90K |
0.021x | +152.79% |
| 2014-12-31 | €7.68 Million ≈ $8.97 Million |
€-303.79K ≈ $-355.16K |
-0.040x | -- |
About Biotechnology Assets S.A.
Biotechnology Assets, S.A. develops and markets biotechnological assets for applications in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industries in Spain and internationally. It offers SPLITTERA, a protein engineering tool that allows the conjugation of proteins through the formation of new peptide bonds; universal switchable split-chimeric antigen receptor (CAR); VA… Read more